Literature DB >> 19746238

The survival of osteosarcoma patients 10 years old or younger is not worse than the survival of older patients: a retrospective analysis.

Jun Ah Lee1, Dong Ho Kim, Jung Sub Lim, Kyung Duk Park, Won Seok Song, Soo-Yong Lee, Dae-Geun Jeon.   

Abstract

PURPOSE: This study aimed to assess whether a young age at the time of diagnosis with osteosarcoma has value to predict the prognosis.
MATERIALS AND METHODS: Sixty-seven children with stage II osteosarcoma were stratified according to the age of 10. There were 32 preadolescents (<or=10 years) and 35 adolescents (10<age<or=15 years). The patients were analyzed for their clinical characteristics, the histologic response to preoperative chemotherapy, event-free survival (EFS) and the patterns of relapse.
RESULTS: After a median follow-up of 54 months (range: 6 approximately 153 months), the 5-year EFS of the preadolescent and adolescent groups was 64.5+/-9.3% and 58.2+/-9.1%, respectively, and age did not have any statistical significance for survival (p=0.55). Cox regression analysis revealed that both the serum level of alkaline phosphatase and the histologic response to preoperative chemotherapy were significantly related to survival of the 67 patients. Those patients aged less than 7 years responded poorly to preoperative chemotherapy and their rate of amputation was 43%. However, their 5-year EFS was not statistically different from the older patients (57.1+/-18.7 vs 67.7+/-6.3%, respectively, p=0.58).
CONCLUSIONS: We could not find any statistical difference in the clinical characteristics and survival from osteosarcoma for the preadolescents and adolescents, so the current approach of having the same protocol for both groups of patients seems to be reasonable.

Entities:  

Keywords:  Age; Osteosarcoma; Preadolescents; Prognosis

Year:  2007        PMID: 19746238      PMCID: PMC2739368          DOI: 10.4143/crt.2007.39.4.160

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  17 in total

1.  Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience.

Authors:  M Hudson; M R Jaffe; N Jaffe; A Ayala; A K Raymond; H Carrasco; S Wallace; J Murray; R Robertson
Journal:  J Clin Oncol       Date:  1990-12       Impact factor: 44.544

2.  Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

Authors:  W B London; R P Castleberry; K K Matthay; A T Look; R C Seeger; H Shimada; P Thorner; G Brodeur; J M Maris; C P Reynolds; S L Cohn
Journal:  J Clin Oncol       Date:  2005-08-22       Impact factor: 44.544

3.  The National Cancer Data Base report on patterns of childhood cancers in the United States.

Authors:  A Grovas; A Fremgen; A Rauck; F B Ruymann; C L Hutchinson; D P Winchester; H R Menck
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

4.  Osteosarcoma in preadolescent patients.

Authors:  M Rytting; P Pearson; A K Raymond; A Ayala; J Murray; A W Yasko; M Johnson; N Jaffe
Journal:  Clin Orthop Relat Res       Date:  2000-04       Impact factor: 4.176

5.  Primary high-grade osteosarcoma: comparison between preadolescent and older patients.

Authors:  Gaetano Bacci; Alessandra Longhi; Franco Bertoni; Patrizia Bacchini; Pietro Ruggeri; Michela Versari; Piero Picci
Journal:  J Pediatr Hematol Oncol       Date:  2005-03       Impact factor: 1.289

6.  OSTEOGENIC SARCOMA IN CHILDREN.

Authors:  R J MCKENNA; C P SCHWINN; N L HIGINBOTHAM
Journal:  Calif Med       Date:  1965-09

7.  Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.

Authors:  N Fuchs; S S Bielack; D Epler; P Bieling; G Delling; D Körholz; N Graf; U Heise; H Jürgens; R Kotz; M Salzer-Kuntschik; P Weinel; M Werner; K Winkler
Journal:  Ann Oncol       Date:  1998-08       Impact factor: 32.976

8.  Osteosarcoma in young children.

Authors:  H Kozakewich; A R Perez-Atayde; A M Goorin; R H Wilkinson; M C Gebhardt; G F Vawter
Journal:  Cancer       Date:  1991-02-01       Impact factor: 6.860

9.  Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group.

Authors:  J D Buckley; T W Pendergrass; C M Buckley; D J Pritchard; M E Nesbit; A J Provisor; L L Robison
Journal:  Cancer       Date:  1998-10-01       Impact factor: 6.860

Review 10.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

View more
  6 in total

1.  Osteosarcoma in children 5 years of age or younger at initial diagnosis.

Authors:  Jennifer Worch; Katherine K Matthay; John Neuhaus; Robert Goldsby; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

2.  The relation of tumour necrosis and survival in patients with osteosarcoma.

Authors:  Xin Li; Adedayo O Ashana; Vincent M Moretti; Richard D Lackman
Journal:  Int Orthop       Date:  2011-02-26       Impact factor: 3.075

3.  Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in South Texas.

Authors:  Aaron J Sugalski; Alisha Jiwani; Norma S Ketchum; John Cornell; Ronald Williams; Josefine Heim-Hall; Jaclyn Y Hung; Anne-Marie Langevin
Journal:  J Pediatr Hematol Oncol       Date:  2014-08       Impact factor: 1.289

4.  Identification of osteosarcoma-related specific proteins in serum samples using surface-enhanced laser desorption/ionization-time-of-flight mass spectrometry.

Authors:  Jianli Gu; Jitian Li; Manyu Huang; Zhiyong Zhang; Dongsheng Li; Guoying Song; Xingpo Ding; Wuyin Li
Journal:  J Immunol Res       Date:  2014-04-24       Impact factor: 4.818

Review 5.  Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data.

Authors:  Hai-Yong Ren; Ling-Ling Sun; Heng-Yuan Li; Zhao-Ming Ye
Journal:  Biomed Res Int       Date:  2015-11-04       Impact factor: 3.411

6.  miR-202-5p inhibits the migration and invasion of osteosarcoma cells by targeting ROCK1.

Authors:  Congda Li; Deying Ma; Jinhu Yang; Xiangbo Lin; Bo Chen
Journal:  Oncol Lett       Date:  2018-05-10       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.